###begin article-title 0
###xml 143 151 <span type="species:ncbi:9606">Patients</span>
Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
###end article-title 0
###begin p 1
Conceived and designed the experiments: VG JS. Performed the experiments: CP PM MT DM MT. Contributed reagents/materials/analysis tools: IB DM AK. Wrote the paper: MSR RR. Supervised the Laboratory work: MT. Evaluation of the samples: AK ES. Performed the statistical analyses: MSR JJS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 320 328 <span type="species:ncbi:9606">patients</span>
Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus docetaxel in advanced non-small-cell lung cancer (NSCLC) patients.
###end p 3
###begin title 4
Methodology and Principal Findings
###end title 4
###begin p 5
###xml 372 373 372 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 547 548 547 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 573 574 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 666 667 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 890 891 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
Tumor samples were collected from 102 chemotherapy-naive advanced NSCLC patients treated with gemcitabine plus docetaxel as part of a randomized trial. RRM1, RRM2 and BRCA1 mRNA levels were assessed by quantitative PCR and correlated with response, time to progression and survival. As BRCA1 levels increased, the probability of response increased (Odds Ratio [OR], 1.09: p = 0.01) and the risk of progression decreased (hazard ratio [HR], 0.99; p = 0.36). As RRM1 and RRM2 levels increased, the probability of response decreased (RRM1: OR, 0.97; p = 0.82; RRM2: OR, 0.94; p<0.0001) and the risk of progression increased (RRM1: HR, 1.02; p = 0.001; RRM2: HR, 1.005; p = 0.01). An interaction observed between BRCA1 and RRM1 allowed patients to be classified in three risk groups according to combinations of gene expression levels, with times to progression of 10.13, 4.17 and 2.30 months (p = 0.001). Low BRCA1 expression was the only factor significantly associated with longer time to progression in 31 patients receiving cisplatin-based second-line therapy.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 93 101 <span type="species:ncbi:9606">patients</span>
The mRNA expression of BRCA1, RRM1 and RRM2 is potentially a useful tool for selecting NSCLC patients for individualized chemotherapy and warrants further investigation in prospective studies.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 76 79 76 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Jemal1">[1]</xref>
###xml 203 206 203 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Burdett1">[2]</xref>
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Schiller1">[3]</xref>
###xml 684 687 684 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias1">[4]</xref>
###xml 689 692 689 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 1058 1061 1058 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Cobo1">[6]</xref>
###xml 1386 1389 1386 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Booton1">[7]</xref>
###xml 1648 1651 1648 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell1">[8]</xref>
###xml 1653 1656 1653 1656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell2">[9]</xref>
###xml 1658 1662 1658 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Ceppi1">[10]</xref>
###xml 1909 1913 1909 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Simon1">[11]</xref>
###xml 840 848 <span type="species:ncbi:9606">Patients</span>
###xml 931 939 <span type="species:ncbi:9606">patients</span>
###xml 1338 1346 <span type="species:ncbi:9606">patients</span>
###xml 1450 1458 <span type="species:ncbi:9606">patients</span>
###xml 1717 1725 <span type="species:ncbi:9606">patients</span>
###xml 1901 1909 <span type="species:ncbi:9606">patients</span>
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer death[1], with little improvement in survival regardless of the type of chemotherapy used, either in combination or as single agents[2]. Combinations of third-generation cytotoxic agents, such as taxanes, vinorelbine and gemcitabine, with cisplatin have emerged as new standards. In several phase III clinical trials in advanced NSCLC, the combination of platinum with taxanes attained median survival times of 8-11 months and 1-year survival of 31-46%[3]. Non-platinum-based combinations with gemcitabine plus docetaxel or paclitaxel have yielded a similar survival benefit with a more favorable toxicity profile[4], [5]. In order to further improve survival, a phase III trial of customized cisplatin according to ERCC1 mRNA levels in stage IV NSCLC was carried out. Patients in the control arm received cisplatin plus docetaxel, while in the genotypic arm, patients with low ERCC1 levels received cisplatin plus docetaxel and those with high levels received gemcitabine plus docetaxel[6]. Although objective response was higher in the genotypic arm than in the control arm (50.7% vs 39.3%), this did not translate to improved survival. The British Thoracic Oncology Group trial (BTOG1) also found no association between ERCC1 levels and survival in advanced NSCLC patients treated with docetaxel plus carboplatin[7]. Retrospective studies of stage IV NSCLC have reported that patients with low ERCC1 or RRM1 mRNA levels had a median survival up to 15 months when treated with gemcitabine plus cisplatin, with more significant differences in survival according to RRM1 levels[8], [9], [10]. A feasibility study of customized treatment in NSCLC patients with high ERCC1 and low ribonucleotide reductase subunit M1 (RRM1) mRNA expression found that gemcitabine plus docetaxel could be the optimal combination for this subgroup of patients[11].
###end p 9
###begin p 10
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Takamizawa1">[12]</xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Johnson1">[13]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Davidson1">[14]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Goan1">[15]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Duxbury1">[16]</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Souglakos1">[17]</xref>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
RRM1 and RRM2 are encoded by different genes on separate chromosomes and their mRNAs are differentially expressed throughout the cell cycle. Reduced expression of let-7 microRNA (miRNA) is frequently observed in NSCLC[12] and often leads to overexpression of RRM1 and RRM2[13]. Resistance to gemcitabine has been associated with both RRM1 and RRM2 overexpression[14], [15]. Small interfering RNA targeting RRM2 enhanced chemosensitivity to gemcitabine in pancreatic adenocarcinoma[16]. In our study of metastatic lung adenocarcinoma patients treated with gemcitabine plus docetaxel, patients with low levels of both RRM1 and RRM2 had a significantly higher response rate (60% vs 14.2%), time to progression (9.9 vs 2.3 months), and overall survival (15.4 vs 3.6 months) than patients with high levels of both genes[17].
###end p 10
###begin p 11
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell3">[18]</xref>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Taron1">[19]</xref>
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell4">[20]</xref>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRM1</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRM2</italic>
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Johnson1">[13]</xref>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRM1</italic>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Deeb1">[21]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 739 743 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell3">[18]</xref>
###xml 247 251 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
A close correlation has also been observed between expression levels of RRM1 and BRCA1[18], [19], [20], and the loss of let-7 has been shown to upregulate BRCA1 as well as RRM1 and RRM2[13]. In addition, both BRCA1 and RRM1 are upregulated in the SV40 T/t-antigen signature[21]. BRCA1 expression confers differential chemosensitivity in cancer cell lines[22], [23]. Ovarian cancer patients in the lowest terciles of BRCA1 expression showed sensitivity to cisplatin and resistance to paclitaxel and docetaxel, while those in the highest terciles had resistance to cisplatin and sensitivity to paclitaxel and docetaxel[23]. Low levels of BRCA1 also correlated with increased survival in NSCLC patients treated with gemcitabine plus cisplatin[18].
###end p 11
###begin p 12
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Souglakos1">[17]</xref>
###xml 360 363 360 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
In order to validate our previous findings on RRM1 and RRM2[17] and to further investigate the role of BRCA1 in taxane sensitivity and resistance, we retrospectively analyzed a series of tumor samples from advanced NSCLC patients treated with gemcitabine plus docetaxel in a randomized phase III trial carried out by the Hellenic Oncology Research Group (HORG)[5].
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 14
###begin p 15
###xml 244 247 244 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 596 597 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 689 690 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 887 890 883 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
###xml 500 508 <span type="species:ncbi:9606">Patients</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
###xml 798 805 <span type="species:ncbi:9606">Patient</span>
Tumor samples were collected from primary tumors from patients with histologically confirmed inoperable stage IIIB and IV NSCLC, who were included in the experimental arm of a HORG randomized trial carried out from April 1999 to September 2002 [5] (no trial registration required before 2005). Eligibility criteria have been previously reported. The study was approved by the Ethics Committees of the participating hospitals, and all patients gave their signed informed consent prior to study entry. Patients received first-line gemcitabine (Gemzar(R); Eli Lilly, Indianapolis, IN, USA) 1000 mg/m2 on days 1 and 8 and docetaxel (Taxotere(R); Sanofi-Aventis, Collegeville, NJ, USA) 100 mg/m2 on day 8, with human granulocyte colony-stimulating factor support every 3 weeks, as previously described. Patient evaluation was performed at baseline and after every three cycles of chemotherapy[5].
###end p 15
###begin title 16
Study design
###end title 16
###begin p 17
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
The present study was a retrospective analysis of the prognostic value of BRCA1, RRM1 and RRM2 mRNA expression in NSCLC patients treated with first-line gemcitabine plus docetaxel. All available tumor biopsies of the primary tumor with more than 100 cells per section were included in the analysis. All efficacy results were assessed for all enrolled patients on an intent-to-treat basis.
###end p 17
###begin title 18
Gene expression analysis
###end title 18
###begin p 19
###xml 761 768 761 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s005">Text S1</xref>
All paraffin-embedded tumors were reviewed by two independent pathologists to define the most appropriate tumor area for microdissection to ensure a minimum of 90% of tumor cells. Malignant cells were procured using an Eppendorf piezoelectric microdissector (Eppendorf, Hamburg, Germany). RNA was purified by trizol LS method (Invitrogen, Carlsbad, CA, USA) followed by isopropanol precipitation and DNase treatment (Ambion, Austin, TX, USA). cDNA synthesis was performed using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Relative quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). (For further details on the gene expression analysis, see Text S1).
###end p 19
###begin title 20
Statistical analyses
###end title 20
###begin p 21
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Therasse1">[24]</xref>
Besides analyzing the expression levels of each gene as a continuous variable, gene expression was also categorized in terciles in order to explore the risk trend of the gene variables and in order to easily identify groups of gene expression levels with different risk. Responses were recorded according to the RECIST criteria[24]. Median time to tumor progression and overall survival were calculated from the start of treatment to the first documented disease progression or death, respectively.
###end p 21
###begin p 22
The potential association between baseline characteristics, response and gene expression levels were compared with either the two-sided Fisher's exact test or the Chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. The normality of continuous variables was verified with a Kolmogorov-Smirnov test. The Spearman test was used to evaluate the correlation between BRCA1, RRM1 and RRM2 mRNA expression. All potential risk factors for response were evaluated in a univariate analysis, and a multivariate logistic regression analysis, with adjusted odd ratios and their 95% confidence intervals (CI), was used to evaluate which of the factors had a significant influence on response. The Hosmer-Lemeshow likelihood test was used to assess the goodness of fit.
###end p 22
###begin p 23
###xml 820 821 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The association of risk factors with time-to-event endpoints was analyzed with the log-rank test, and the Kaplan-Meier method was used to plot the corresponding time-to-progression and survival curves. A univariate Cox regression analysis, with hazard ratios and 95% CIs, was used to assess the association between each potential prognostic factor and survival and time to progression. These factors were then included in a multivariate Cox proportional hazards regression model with a stepwise procedure (both forward and backward) to evaluate the independent significance of different variables on survival and time to progression. The likelihood ratio test was used to assess the goodness of fit, and the Wald's test was used to assess the coefficient significance. In the case of potential multiple comparisons, the p-values were corrected with the Bonferroni correction.
###end p 23
###begin p 24
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
All statistical calculations were performed with SPSS, version 15.0 (SPSS, Inc., Chicago, IL, USA). Two-sided p-values of less than 0.05 were considered significant.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics and clinical outcome
###end title 26
###begin p 27
###xml 32 35 32 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 174 180 174 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003695-g001">Fig. 1</xref>
###xml 502 509 502 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t001">Table 1</xref>
###xml 619 622 619 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 465 472 <span type="species:ncbi:9606">Patient</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
In the original randomized trial[5], 209 NSCLC patients were treated with gemcitabine plus docetaxel; 107 were not included in the present study due to lack of tumor tissue (Fig. 1). Clinical data and samples from primary tumors were available for 102 patients, who were included in the present study. Amplification of BRCA1, RRM1 and RRM2 was successful in 96 samples. Eighty-one were adenocarcinomas, ten squamous cell carcinomas, and five large-cell carcinomas. Patient characteristics are shown in Table 1. In the original trial, the response rate was 30%, time to progression 4 months, and median survival 9 months[5]. Outcome for the 96 patients assessed in the present study was similar: response rate 30.5%, time to progression 4.2 months, and median survival 10.5 months.
###end p 27
###begin title 28
Chart showing the process of obtaining archival paraffin-embedded tumor biopsies for the assessment of BRCA1, RRM1 and RRM2 mRNA expression.
###end title 28
###begin p 29
###xml 132 135 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Georgoulias2">[5]</xref>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
Two hundred and nine patients were treated with gemcitabine plus docetaxel as part of a phase III randomized trial in advanced NSCLC[5]. Tumor biopsy was obtained from a total of 102 patients; 68 patients were ruled out because only cytological specimens were available, and 39 bronchial biopsies contained too few tumor cells for analysis. mRNA expression analysis was feasible in tumor samples from 96 of 102 patients.
###end p 29
###begin title 30
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end title 30
###begin title 31
BRCA1, RRM1 and RRM2 mRNA expression levels
###end title 31
###begin p 32
###xml 138 145 138 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t001">Table 1</xref>
###xml 204 211 204 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s001">Fig. S1</xref>
###xml 401 402 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 490 491 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 611 612 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 622 629 616 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t001">Table 1</xref>
Median mRNA expression levels were 3.64 (range 0-34.37) for BRCA1, 0.82 (range 0-325.23) for RRM1 and 27.16 (range 0.97-256.84) for RRM2 (Table 1). Expression levels did not follow a normal distribution (Fig. S1). There was no correlation between age, gender, PS, or disease stage and BRCA1, RRM1 or RRM2 mRNA levels. Significant correlations were observed overall between BRCA1 and RRM1 (rho = 0.27; p = 0.008) and a non-significant trend to correlation between RRM1 and RRM2 (rho = 0.19; p = 0.06) mRNA levels. There was also a significant inverse correlation between BRCA1 and RRM2 mRNA levels (rho = -0.25; p = 0.02). Table 1 also shows the mRNA expression levels of the three genes according to terciles.
###end p 32
###begin title 33
Gene expression and response to treatment
###end title 33
###begin p 34
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 396 397 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
In order to predict response to treatment, a logistic regression model was fitted for the expression of each gene as a continuous variable. As BRCA1 levels increased, the probability of response increased significantly (Odds Ratio [OR] = 1.09; 95% CI, 1.02-1.16; p = 0.01). In contrast, as RRM2 levels increased, the probability of response decreased significantly (OR = 0.94; 95% CI, 0.91-0.97; p<0.0001). A similar but non-significant trend was observed for RRM1 levels (OR = 0.97; 95% CI, 0.77-1.23; p = 0.82).
###end p 34
###begin p 35
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 289 296 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t002">Table 2</xref>
When responders were classified according to their gene expression levels by terciles, the majority of responders had high BRCA1 expression and low RRM2 expression: 58.6% in the highest tercile of BRCA1 expression (p = 0.002) and 72.4% in the lowest tercile of RRM2 expression (p<0.0001) (Table 2).
###end p 35
###begin title 36
Univariate and multivariate analyses for response to treatment.
###end title 36
###begin p 37
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, odds ratio; T, terciles; PS, performance status.
###end p 37
###begin p 38
###xml 185 192 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t002">Table 2</xref>
###xml 384 391 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t002">Table 2</xref>
The univariate logistic regression analysis revealed that low RRM2 expression, ECOG PS 0, and high BRCA1 expression were significantly associated with a higher probability of response (Table 2). In the multivariate logistic regression analysis of these variables together with RRM1 and disease stage, only low RRM2 expression emerged as an independent predictive factor for response (Table 2).
###end p 38
###begin title 39
Gene expression and time to progression
###end title 39
###begin p 40
###xml 188 189 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 199 206 199 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t003">Table 3</xref>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 609 610 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The univariate analysis for time to progression revealed that the only clinical variable associated with time to progression was PS (Hazard Ratio [HR] for PS 1-2, 1.55; 95% CI, 0.99-2.41; p = 0.05) (Table 3). The univariate analysis for time to progression according to gene expression levels as continuous variables showed that as RRM1 and RRM2 values increased, the risk of progression increased significantly: RRM1 (HR, 1.02; 95% CI, 1.01-1.02; p = 0.001); RRM2 (HR, 1.005; 95% CI, 1.001-1.008; p = 0.01). However, as BRCA1 levels increased, the risk of progression decreased (HR, 0.99; 95% CI, 0.95-1.02; p = 0.36).
###end p 40
###begin title 41
Median time to progression according to gene expression, ECOG PS and disease stage.
###end title 41
###begin p 42
TTP, time to progression; HR, hazard ratio; T, tercile; PS, performance status.
###end p 42
###begin p 43
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 321 322 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 388 389 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 461 468 461 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t003">Table 3</xref>
###xml 664 665 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 726 727 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 737 744 737 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t003">Table 3</xref>
###xml 820 827 820 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t003">Table 3</xref>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
When gene expression levels were categorized by terciles, the risk of progression was greater for patients in the intermediate and highest terciles of RRM1 and RRM2 than for those in the lowest tercile: RRM1 intermediate tercile (HR, 1.20; 95% CI, 0.72-1.97; p = 0.49); RRM1 highest tercile (HR, 1.51; 95% CI, 0.91-2.51; p = 0.11); RRM2 intermediate tercile (HR, 1.28; 95% CI, 0.77-2.13; p = 0.35); RRM2 highest tercile (HR, 1.93; 95% CI, 1.16-3.22; p = 0.01) (Table 3). The risk of progression was greater for patients in the intermediate and lowest tercile of BRCA1 than for those in the highest tercile: BRCA1 intermediate tercile (HR, 1.33; 95% CI, 0.80-2.22; p = 0.28); BRCA1 lowest tercile (HR, 1.51; 95% CI, 0.91-2.49; p = 0.11) (Table 3). Time to progression according to gene expression by terciles is shown in Table 3.
###end p 43
###begin p 44
A multivariate model was fitted with the variables examined in the univariate setting.
###end p 44
###begin p 45
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 215 223 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s002">Table S1</xref>
###xml 278 286 278 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s003">Table S2</xref>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
When interaction terms were examined to check whether they significantly improved the fit, none was significant except for BRCA*RRM1, which gave a significance of p = 0.02 to the model without the interaction term (Table S1). The multivariate model was then stratified by RRM1 (Table S2) and without disease stage. In this model, patients in the lowest tercile of RRM2 continued to have the lowest risk of progression, independently of RRM1 levels.
###end p 45
###begin p 46
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
Patients were classified in three groups according to risk of progression, based on the interaction observed between RRM1 and BRCA1. Twenty-four patients were in the low-risk group (intermediate BRCA1+low RRM1; high BRCA1+low RRM1; high BRCA1+intermediate RRM1); 42 patients were in the intermediate-risk group (low BRCA1+low RRM1; intermediate BRCA1+high RRM1; high BRCA1+high RRM1); and 30 patients were in the high-risk group (low BRCA1+intermediate RRM1; intermediate BRCA1+intermediate RRM1; low BRCA1+high RRM1).
###end p 46
###begin p 47
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 268 277 268 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s003">Tables S2</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s004">S3</xref>
###xml 283 289 283 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003695-g002">Fig. 2</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
The median time to progression was 10.13 months (95% CI, 7.65-12.62) for patients in the low-risk group, 4.17 months (95% CI, 72.90-5.44) for patients in the intermediate-risk group, and 2.30 months (95% CI, 1.76-2.84) for patients in the high-risk group (p = 0.001) (Tables S2, S3; Fig. 2).
###end p 47
###begin title 48
Time to progression according to risk groups.
###end title 48
###begin p 49
###xml 775 776 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 796 805 796 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s003">Tables S2</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003695.s004">S3</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
Patients were classified in three groups according to risk of progression, based on the interaction observed between RRM1 and BRCA1. Twenty-four patients were in the low-risk group (intermediate BRCA1+low RRM1; high BRCA1+low RRM1; high BRCA1+intermediate RRM1); 42 patients were in the intermediate-risk group (low BRCA1+low RRM1; intermediate BRCA1+high RRM1; high BRCA1+high RRM1); and 30 patients were in the high-risk group (low BRCA1+intermediate RRM1; intermediate BRCA1+intermediate RRM1; low BRCA1+high RRM1). The median time to progression was 10.13 months (95% CI, 7.65-12.62) for patients in the low-risk group, 4.17 months (95% CI, 72.90-5.44) for patients in the intermediate-risk group, and 2.30 months (95% CI, 1.76-2.84) for patients in the high-risk group (p = 0.001) (See also Tables S2, S3).
###end p 49
###begin title 50
Gene expression and survival
###end title 50
###begin p 51
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 139 146 139 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t004">Table 4</xref>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 595 602 595 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t004">Table 4</xref>
###xml 743 750 743 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t004">Table 4</xref>
In the univariate analysis of survival, the only significant clinical variable was PS (HR for PS 1-2, 1.94; 95% CI, 1.21-3.12; p = 0.005) (Table 4). As RRM1 and RRM2 values increased, the risk of death increased: RRM1 (HR, 1.01; 95% CI, 1.00-1.02; p = 0.005); RRM2 (HR, 1.004; 95% CI, 1.00-1.008; p = 0.06). However, as BRCA1 levels increased, the risk of death decreased (HR, 0.99; 95% CI, 0.96-1.03; p = 0.60). When gene expression levels were categorized in terciles, the same pattern of increased risk of death was observed for higher levels of both RRM1 and RRM2 and lower levels of BRCA1 (Table 4). In the multivariate model including all the variables from the univariate analysis, only PS emerged as a significant factor for survival (Table 4).
###end p 51
###begin title 52
Median survival according to gene expression, PS and disease stage.
###end title 52
###begin p 53
MS, median survival; HR, hazard ratio; T, tercile; PS, performance status.
###end p 53
###begin title 54
Gene expression and second-line treatment
###end title 54
###begin p 55
###xml 724 725 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 736 743 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t005">Table 5</xref>
###xml 745 751 745 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003695-g003">Fig. 3</xref>
###xml 937 944 937 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t006">Table 6</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 897 905 <span type="species:ncbi:9606">patients</span>
Second-line therapy was administered in 31 patients, 90.3% of whom received cisplatin-based chemotherapy. There were no differences in gene expression levels between patients receiving and those not receiving second-line therapy. Time to progression for all 31 patients calculated from the start of second-line therapy was 3.40 months (95% CI, 2.73-4.07). In contrast to the pattern observed with first-line therapy, low levels of BRCA1 were significantly associated with the lowest risk of progression to second-line therapy. Median time to progression was 6.60 months for patients in the lowest tercile, 2 months for those in the intermediate tercile, and 2.40 months for those in the highest tercile of BRCA1 expression (p = 0.004) (Table 5, Fig. 3). BRCA1 mRNA expression emerged as the only significant factor in both the univariate and multivariate analyses of time to progression in the 31 patients receiving second-line therapy (Table 6).
###end p 55
###begin title 56
Time to progression after first-line treatment according to BRCA1 terciles.
###end title 56
###begin p 57
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 380 387 380 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003695-t005">Table 5</xref>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
In contrast to the pattern observed with first-line therapy, low levels of BRCA1 were significantly associated with the lowest risk of progression to second-line therapy. Median time to progression was 6.60 months for patients in the lowest tercile, 2 months for those in the intermediate tercile, and 2.40 months for those in the highest tercile of BRCA1 expression (p = 0.004) (Table 5). (For further details, see text.)
###end p 57
###begin title 58
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Time to progression after first-line treatment according to gene expression levels in 31 patients receiving second-line therapy.
###end title 58
###begin p 59
TTP, time to progression; T, tercile.
###end p 59
###begin title 60
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Univariate and multivariate analyses of time to progression after first-line therapy for 31 patients receiving second-line treatment.
###end title 60
###begin p 61
HR, hazard ratio; PS, performance status.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Souglakos1">[17]</xref>
###xml 915 919 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Xu1">[25]</xref>
###xml 953 956 953 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell1">[8]</xref>
###xml 958 961 958 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell2">[9]</xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">Patients</span>
###xml 616 623 <span type="species:ncbi:9606">patient</span>
###xml 810 825 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1041 1049 <span type="species:ncbi:9606">patients</span>
The present study has found an inverse correlation between RRM2 mRNA expression and response to gemcitabine plus docetaxel in advanced NSCLC patients. Patients with low RRM2 mRNA expression attained a significantly higher response rate and time to progression than those with high RRM2 expression. In addition, RRM2 mRNA expression was revealed as an independent predictive factor for response. These results confirm our earlier findings in a small cohort of lung adenocarcinomas treated with the same regimen[17]. Although median RRM2 levels were different in the two studies, possibly due to slight differences in patient populations or in some steps of the RNA extraction and PCR quantification procedures, the correlation between mRNA levels and clinical results was similar in both studies. Intriguingly, transgenic mice developed lung adenocarcinoma but not other tumors in the presence of RRM2 overexpression[25]. In earlier retrospective studies[8], [9], we found that high levels of RRM1 predicted longer survival in stage IV NSCLC patients treated with gemcitabine plus cisplatin but not in those treated with cisplatin-based regimens without gemcitabine.
###end p 63
###begin p 64
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Matsuoka1">[26]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Husain1">[27]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Lafarge1">[28]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Lafarge1">[28]</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 509 513 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Husain1">[27]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Lafarge1">[28]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Lafarge1">[28]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn2">[23]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Quinn1">[22]</xref>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
The significant correlation between the top tercile of BRCA1 mRNA expression and improved response observed in the present study adds to the growing body of evidence that BRCA1 is a crucial mediator of DNA damage response[26]. Low BRCA1 expression confers increased sensitivity to cisplatin[22], [23], [27], [28] and etoposide[22] and resistance to antimicrotubule drugs, such as paclitaxel[22], [23], [28], docetaxel[23] and vinorelbine[22], while high BRCA1 expression leads to resistance to cisplatin[22], [23], [27], [28] and etoposide[22] and sensitivity to paclitaxel[22], [23], [28], docetaxel[23] and vinorelbine[22]. In the present study, patients with low BRCA1 mRNA expression had poor response and time to progression to first-line gemcitabine plus docetaxel; in contrast, they obtained the maximum benefit from second-line cisplatin-based treatment, attaining a median time to progression of 6.6 months.
###end p 64
###begin p 65
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mad2</italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BubR1</italic>
###xml 365 369 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Sudo1">[29]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Chabalier1">[30]</xref>
Several layers of evidence show that the abrogation of BRCA1 function leads to resistance to antimicrotubule drugs. Spindle checkpoint defects are associated with resistance to taxanes and vinca alkaloids. Suppression of Mad2 or BubR1 in paclitaxel-treated breast cancer MCF-7 cells abolishes spindle checkpoint function, resulting in enhanced paclitaxel resistance[29]. In addition, downregulation of BRCA1 expression mediates paclitaxel resistance through premature inactivation of spindle checkpoint in MCF-7 cells via downregulation of BubR1[30].
###end p 65
###begin p 66
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Bae1">[31]</xref>
###xml 820 825 820 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 851 856 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Bae1">[31]</xref>
###xml 1101 1105 1101 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bub1</italic>
###xml 1110 1115 1110 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BubR1</italic>
###xml 1245 1249 1245 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Bae1">[31]</xref>
BRCA1 dysfunction is closely related to spindle checkpoint defects but not to G2 phase alterations. Indeed, a set of gene expression alterations due to the knockdown of endogenous BRCA1 has been identified in prostate (DU-145) and breast (MCF-7) cancer cells by DNA microarray analysis[31]. Various categories of genes are downregulated in BRCA1-knockdown cells, including genes involved in transcription and cell cycle regulation and in DNA replication and repair. BRCA1-short interference RNAs (siRNAs) also caused the downregulation of DNA topoisomerase II alpha (TOP2A), an enzyme involved in DNA replication and in both the DNA damage-responsive G2 checkpoint and the G2 decatenation checkpoint. This checkpoint requires TOP2A, ATR, WRN (Werner's syndrome helicase), and BRCA1; it is defective in cells with mutant BRCA1. However, in contrast to BRCA1-mutant cell lines, knockdown of wild-type BRCA1 did not attenuate this checkpoint but showed attenuation of the mitotic spindle checkpoint[31]. BRCA1 positively regulates the expression of many genes involved in the spindle checkpoint, such as Bub1 and BubR1. Consistent with these findings, cells pretreated with BRCA1-siRNAs failed to arrest in metaphase after treatment with nocodazole[31].
###end p 66
###begin p 67
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRM2</italic>
###xml 95 125 95 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dihydrofolate reductase (DHFR)</italic>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Bae1">[31]</xref>
###xml 492 497 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bub1b</italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TOP2A</italic>
###xml 506 510 506 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DHFR</italic>
###xml 512 537 512 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">thymidylate synthase (TS)</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RRM1</italic>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Deeb1">[21]</xref>
###xml 423 428 <span type="species:ncbi:10090">mouse</span>
Interestingly, BRCA1-siRNAs also caused downregulation of metabolism genes, including RRM2 and dihydrofolate reductase (DHFR)[31]. Moreover, an integrated gene signature from multiple transgenic models of epithelial cancers intrinsic to the functions of the Simian virus 40T/t-antigens is composed of genes regulating cell replication, proliferation and DNA repair. BRCA1 is overexpressed in three T/t-antigenic transgenic mouse models (breast, lung, prostate), as are other genes, including Bub1b, TOP2A, DHFR, thymidylate synthase (TS), and RRM1[21].
###end p 67
###begin p 68
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Fossella1">[32]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Scagliotti1">[33]</xref>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 874 878 874 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EGFR</italic>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Sequist1">[34]</xref>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 746 754 <span type="species:ncbi:9606">patients</span>
###xml 860 868 <span type="species:ncbi:9606">patients</span>
The limited efficacy of current chemotherapy approaches is epitomized in metastatic NSCLC, where time to progression ranges from 5.2 to 5.5 months, with different combinations of chemotherapy, such as docetaxel plus cisplatin[32] or new compounds like pemetrexed (an inhibitor of TS and DHFR) plus cisplatin[33]. Therefore, in spite of the retrospective nature of the present study, a time to progression of 10 months in 24 of 96 patients in the low-risk group (high BRCA1 and low RRM1 levels), treated with docetaxel plus gemcitabine, represents a promising new landmark that merits validation in a prospective trial of customized chemotherapy. These clinical findings are similar to those obtained with EGFR tyrosine kinase inhibitors in NSCLC patients harboring EGFR mutations. In the only prospective study reported of treatment with gefitinib in 31 NSCLC patients with EGFR mutations, a time to progression of 9.2 months was attained[34].
###end p 68
###begin p 69
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Rosell4">[20]</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Eelen1">[35]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Sobhian1">[36]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Chen1">[37]</xref>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
From the present study, we cannot determine whether the mRNA expression of BRCA1, RRM1 or RRM2 could have a prognostic - as well as a predictive - role. In early-stage, chemonaive, resected NSCLC patients, BRCA1 mRNA expression was the only independent prognostic variable[20]. Similarly, high mRNA expression of the BRCA1-interacting protein BACH1/Brip1 has been found in aggressive breast cancers[35]. In addition, BRCC36 has been shown to be present in the BRCA1-RAP80 complex [36]and is overexpressed in breast cancer, where it confers radioresistance[37]. This highlights the possibility that BRCA1 - or several interacting partners - can confer poor prognosis as well as resistance to cisplatin or other DNA-damaging agents.
###end p 69
###begin p 70
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Deeb1">[21]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003695-Bae1">[31]</xref>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
In summary, our findings indicate that the efficacy of gemcitabine plus docetaxel can be improved when customized according to the mRNA expression of BRCA1, RRM1 and RRM2. It is intriguing to speculate that BRCA1 could become an important predictive marker for customizing pemetrexed plus cisplatin in patients with low BRCA1 levels, since BRCA1 could be a surrogate of DHFR and TS levels[21], [31]. Prospective studies of customized chemotherapy based on the expression of these genes have been opened.
###end p 70
###begin title 71
Supporting Information
###end title 71
###begin p 72
Box plots showing mRNA expression values for BRCA1, RRM1 and RRM2. Numerical values shown on each box plot are values that differ from the median. These numerical values have the probability of belonging to the distribution of these genes.
###end p 72
###begin p 73
(2.25 MB TIF)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin p 75
Interactions for time to progression
###end p 75
###begin p 76
(0.05 MB DOC)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
Multivariate analysis of time to progression stratified by RRM1
###end p 78
###begin p 79
(0.04 MB DOC)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
Median time to progression stratified by RRM1
###end p 81
###begin p 82
(0.04 MB DOC)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
Boukovinas et al - BRCA1
###end p 84
###begin p 85
(0.04 MB DOC)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin title 87
References
###end title 87
###begin article-title 88
Cancer statistics, 2007.
###end article-title 88
###begin article-title 89
###xml 148 155 <span type="species:ncbi:9606">patient</span>
Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs); 2007; Seoul, Korea.
###end article-title 89
###begin article-title 90
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
###end article-title 90
###begin article-title 91
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
###end article-title 91
###begin article-title 92
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
###end article-title 92
###begin article-title 93
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
###end article-title 93
###begin article-title 94
ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
###end article-title 94
###begin article-title 95
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
###end article-title 95
###begin article-title 96
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
###end article-title 96
###begin article-title 97
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
###end article-title 97
###begin article-title 98
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
###end article-title 98
###begin article-title 99
###xml 45 50 <span type="species:ncbi:9606">human</span>
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.
###end article-title 99
###begin article-title 100
###xml 60 65 <span type="species:ncbi:9606">human</span>
The let-7 microRNA represses cell proliferation pathways in human cells.
###end article-title 100
###begin article-title 101
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
###end article-title 101
###begin article-title 102
###xml 108 113 <span type="species:ncbi:9606">human</span>
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.
###end article-title 102
###begin article-title 103
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
###end article-title 103
###begin article-title 104
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
###end article-title 104
###begin article-title 105
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
###end article-title 105
###begin article-title 106
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
###end article-title 106
###begin article-title 107
BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer.
###end article-title 107
###begin article-title 108
###xml 32 36 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
###end article-title 108
###begin article-title 109
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
###end article-title 109
###begin article-title 110
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy.
###end article-title 110
###begin article-title 111
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
###end article-title 111
###begin article-title 112
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms.
###end article-title 112
###begin article-title 113
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
###end article-title 113
###begin article-title 114
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).
###end article-title 114
###begin article-title 115
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
###end article-title 115
###begin article-title 116
Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
###end article-title 116
###begin article-title 117
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
###end article-title 117
###begin article-title 118
BRCA1 regulates gene expression for orderly mitotic progression.
###end article-title 118
###begin article-title 119
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
###end article-title 119
###begin article-title 120
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
###end article-title 120
###begin article-title 121
###xml 24 32 <span type="species:ncbi:9606">patients</span>
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
###end article-title 121
###begin article-title 122
###xml 99 104 <span type="species:ncbi:9606">human</span>
Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
###end article-title 122
###begin article-title 123
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.
###end article-title 123
###begin article-title 124
BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation.
###end article-title 124
###begin p 125
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 125
###begin p 126
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partly supported by the Cretan Association for Biomedical Research (CABR). Dr. John Souglakos is the recipient of a CABR research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 126

